Last reviewed · How we verify
NCT03513887
Noninvasive Tests to Predict the Presence of Esophageal Varices in Patients With Liver Cirrhosis
trial in Cirrhosis in 111 participants. Completed in 12 January 2019.
12 January 2019
Quick facts
| Lead sponsor | Second Affiliated Hospital of Xi'an Jiaotong University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 111 |
| Start date | 28 February 2018 |
| Primary completion | 12 January 2019 |
| Estimated completion | 12 January 2019 |
| Sites | 1 location across China |
Conditions studied
- Cirrhosis — all drugs for Cirrhosis →
Sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Who can join
Adults 18 to 80, any sex, with Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Liver cirrhosis is caused by chronic liver diseases, varices exist in 30 - 60% of patients with liver cirrhosis. Variceal bleeding is one of the most important complications of cirrhosis, accelerating the progression of decompensation to a stage at which the patient is at an extremely high risk of death. Endoscopy is the gold standard for the diagnosis of varices, However, periodic endoscopic screening in all cirrhotic patients might unnecessarily induce an invasive and expensive procedure, ultimately increasing not only the medical workload of endoscopy units, but also the financial burden of patients. To avoid unnecessary endoscopy in low- risk patients, some simple, non-invasive and accurate tests have been developed to identify EVs. Such as Transient elastography (TE) , which is a noninvasive tool that measures liver stiffness (LS) correlating to liver fibrosis stage. Moreover, the LS-spleen size-to-platelet ratio score (LSPS), which is a combination of three simple examination methods (LS, spleen size and platelet count) has been established to accurately predict EVs in patients with cirrhosis. Therefore, investigators design this cross-sectional study to assess these non-invasive tests in predicting the presence of EVs in patients with cirrhosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03513887
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cirrhosis
Currently open trials in the same condition.
- NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
- NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
- NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
- NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
- NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting
Other Second Affiliated Hospital of Xi'an Jiaotong University trials
Trials by the same sponsor.
- NCT07160361 — Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB · Phase 4 · not yet recruiting
- NCT07346456 — Comparison of IOL Formulas in Eyes With PCE≥15µm · completed
- NCT06998589 — Comparison of the Efficacy and Safety of Delicate Pulsed Light and Q-Switched 1064 nm Nd:YAG Laser in the Treatment of P · NA · completed
- NCT07305675 — Effectiveness of a rhGM-CSF-containing Gel on Promoting Recovery After 1927-nm Fractional Thulium Fiber Laser Treatment · NA · completed
- NCT06791005 — A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03513887 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Xi'an Jiaotong University
- Last refreshed: 29 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03513887.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing